Novo Nordisk’s oral semaglutide tablet, known as Rybelsus, is gaining popularity in India for treating diabetes and weight reduction. Sales of the drug have more than doubled in the past year. However, doctors have advised against indiscriminate use of the drug. The success of Rybelsus has led to a tripled anti-obesity market in India.